New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
UP AFTER EARNINGS: PVH Corp. (PVH), up 2.5%... Five Below (FIVE), up 17%... Steelcase (SCS), up 9.5%... Movado (MOV), up 8.3%... ALSO HIGHER: Sirius XM (SIRI), up 1.6% after upgraded at Barclays... Youku Tudou (YOKU), up 7.6% after Marbridge Daily says Tencent (TCEHY) rumored to take 20% stake in the company... Sprouts Farmers Markets (SFM), up 3.4% after better than expected Q1 revenue view... Yongye (YONG), up 13%, after Full Alliance increases going private offer to $7 per share. DOWN AFTER EARNINGS: RGS Energy (RGSE), down 14%... Body Central (BODY), down 22%. ALSO LOWER: Global Geophysical (GGS), down 68% after filing voluntary Chapter 11 petitions... Insmed (INSM), down 8.7% after reporting that ARIKAYCE did not achieve primary endpoint in Phase 2 trial... International Game (IGT), down 7.4% after cutting earnings outlook, 7% of workforce... Abraxas Petroleum (AXAS), down 3.7% following downgrade at Canaccord... Exelixis (EXEL), up 31% after committee determined that its Phase III COMET-1 trial should continue based on lack of sufficient survival benefit to halt the trial.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
15:31 EDTRGSENotable companies reporting after market close
Subscribe for More Information
10:34 EDTIGTOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTMOVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Hold from Buy at KeyBanc... BlackBerry (BBRY) downgraded to Underweight from Equal Weight at Morgan Stanley... Consolidated Edison (ED) downgraded to Sell from Neutral at UBS... Denbury Resources (DNR) downgraded to Hold from Buy at Wunderlich... Synchronoss (SNCR) downgraded to Underperform from Neutral at RW Baird... Total System (TSS) downgraded to Sell from Neutral at Goldman... Movado (MOV) downgraded to Market Perform from Outperform at Barrington... Transocean Partners (RIGP) downgraded to Market Perform from Outperform at Wells Fargo... Seadrill Partners (SDLP) downgraded to Market Perform from Outperform at Wells Fargo... Petrobras (PBR) downgraded to Neutral from Buy at UBS.
07:20 EDTMOVMovado downgraded to Market Perform from Outperform at Barrington
Subscribe for More Information
November 16, 2014
18:57 EDTSIRISirius loses request to dismiss Turtles' lawsuit on pre-1972 songs, NYT says
Subscribe for More Information
13:12 EDTEXELExelixis announces data from trial of XL888 and vemurafenib
Exelixis announced preliminary results from a phase 1 investigator-sponsored trial, IST, evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90, HSP90, in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. Safety and efficacy results support the further investigation of 90 mg of XL888 twice weekly, BIW and vemurafenib 960 mg twice daily,BID, in additional studies that would include a third agent. The trial results were presented today by Keiran Smalley, Ph.D., an investigator on the trial and an associate professor at H. Lee Moffitt Cancer Center, Tampa, Florida, in a late-breaking oral presentation session at the Society for Melanoma Research 2014 International Congress, which is taking place November 13-16, in Zurich, Switzerland. Based on these results, as well as findings from coBRIM, the phase 3 pivotal trial of cobimetinib, an Exelixis-discovered MEK inhibitor, and vemurafenib in previously untreated metastatic melanoma patients with a BRAF V600 mutation, the Moffitt Center plans to initiate a phase 1b IST of the triple combination of vemurafenib, cobimetinib, and XL888 in a similar patient population. “The BRAF inhibitor vemurafenib is active in BRAF-mutated malignant melanoma, but development of resistance is common. Preclinical studies led by Keiran Smalley, Ph.D. suggested that most BRAF inhibitor resistance mechanisms involve proteins that are clients of HSP90, and the preclinical evaluation of XL888 showed that it is highly active in vemurafenib-resistant melanoma models,” said Jeffrey Weber, MD, Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL. “The current phase 1 data show that both drugs can be given together, and compelling initial response results suggest potential cooperative activity.” “About half of metastatic melanoma patients whose tumors harbor a BRAF V600 mutation respond to vemurafenib, but most of them develop resistance and their tumors begin to regrow,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Multiple mechanisms drive this resistance, and the team at Moffitt found that many of them involve upregulation of HSP90 client proteins that are sensitive to XL888. We look forward to supporting the Moffitt team as they continue to evaluate XL888 as part of our IST program.”
November 14, 2014
16:21 EDTMOVOn The Fly: Closing Wrap
Subscribe for More Information
12:58 EDTMOVOn The Fly: Midday Wrap
Subscribe for More Information
12:53 EDTSIRIOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
10:53 EDTMOVMovado tumbles after profit warning, levels to watch
The shares are down over 33% to $25.51 at time of writing. On a long-term basis the $25 area has previously been important support, notably in the spring and summer of 2012. A break below $25 would find next support at $24.65 and $22.50. Resistance is at $26.28.
10:00 EDTMOV, YOKUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:24 EDTYOKUYouku Tudou downgraded to Underweight from Neutral at HSBC
09:23 EDTMOVFossil down 1.4% to $108.25 following profit warning from peer Movado
Subscribe for More Information
09:16 EDTYOKUOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTMOVMovado downgraded to Neutral from Buy at Dougherty
Dougherty downgraded Movado to Neutral following the negative Q3 pre-announcment.
07:20 EDTMOVMovado to host conference call
Conference Call to provide updated outlook for FY15 will be held on November 14 at 8:30 am. Webcast Link
07:09 EDTMOVMovado says will not achieve FY15 financial targets
Subscribe for More Information
07:04 EDTMOVMovado sees FY15 EPS $1.80-$1.85, may not compare to consensus $2.40
Subscribe for More Information
07:04 EDTMOVMovado sees Q4 EPS 18c-23c, may not compare to consensus 50c
Subscribe for More Information
07:02 EDTMOVMovado sees Q3 EPS 86c-87c, may not compare to consensus $1.13
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use